Last reviewed · How we verify
Nevanac
At a glance
| Generic name | Nevanac |
|---|---|
| Also known as | nepafenac, Nepafenac 0.3% Ophthalmic Suspension |
| Sponsor | Santa Casa de Misericordia de Santos |
| Target | Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
- Post-Op Ocular Inflammation
- Postoperative Ocular Pain
Common side effects
- Capsular opacity
- Decreased visual acuity
- Foreign body sensation
- Increased intraocular pressure (IOP)
- Sticky sensation
- Conjunctival edema
- Corneal edema
- Dry eye
- Lid margin crusting
- Ocular discomfort
- Ocular hyperemia
- Ocular pain
Serious adverse events
- Increased bleeding time
- Delayed healing
- Corneal effects
Key clinical trials
- Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy (PHASE4)
- Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation (PHASE2)
- DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC) (PHASE4)
- Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN) (PHASE4)
- Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension (PHASE3)
- Macular Edema Nepafenac vs. Difluprednate Uveitis Trial (PHASE4)
- Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% (PHASE4)
- Post Intravitreal Injection Topical NSAID vs. Patching (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nevanac CI brief — competitive landscape report
- Nevanac updates RSS · CI watch RSS
- Santa Casa de Misericordia de Santos portfolio CI